Sigmoid Pharma is headquartered at the Invent Centre, an advanced technologies incubator on the campus of Dublin City University.
The company, formerly known as Sigmoid Biotechnologies, was founded in 2003 with the goal of developing a new oral drug delivery technology to address the persistent challenges of poor aqueous solubility of small molecules, poor systemic bioavailability of orally administered large molecules as well as optimising controlled release. Having successfully achieved this goal by creating and patenting the SmPill technology, the company changed its name to Sigmoid Pharma in 2007, to reflect its decision to develop a pipeline of proprietary specialty pharmaceutical products using the SmPill technology platform.
Sigmoid has approximately 20 highly trained employees operating in close collaboration with a network of professional service-providers to underpin state-of-the-art development and manufacturing capabilities. Sigmoid operates its own GMP manufacturing facility in the Invent Centre. This facility is licensed by the Irish Medicines Board to manufacture, test and release materials for clinical use.
Sigmoid is privately financed and is led by an experienced team of senior executives